52.95 0.00 (0.00%)
After hours: 4:46PM EST
|Bid||52.22 x 1000|
|Ask||53.28 x 300|
|Day's Range||52.72 - 54.15|
|52 Week Range||16.95 - 63.60|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 19, 2018 - Feb 23, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||58.63|
NEW YORK, NY / ACCESSWIRE / January 15, 2018 / Concert Pharmaceuticals shares crumbled on Friday after it was revealed that the company's CTP-543 treatment could infringe on Incyte's patent and after CEO ...
Several companies made headlines after hours, including Advanced Micro Devices, Inc. (NASDAQ:AMD), EXACT Sciences Corporation (NASDAQ:EXAS) and International Business Machines Corp. (NYSE:IBM). Advanced Micro Devices admitted that its chips may have a vulnerability. About a week ago, the company said that there was almost no risk of AMD chips being affected by a variant of the Spectre vulnerability.
MADISON, Wis., Jan. 11, 2018 /PRNewswire/ -- Exact Sciences Corporation (EXAS) announced today that it has priced its underwritten public offering of 1.0% convertible senior notes due 2025 (the "Notes"), and upsized the offering from $500 million to $600 million aggregate principal amount, pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $90 million aggregate principal amount of Notes. The closing of the offering is expected to occur on January 17, 2018 and is subject to customary closing conditions.
MADISON, Wis., Jan. 11, 2018 /PRNewswire/ -- Exact Sciences Corporation (EXAS) today announced an underwritten public offering of $500 million aggregate principal amount of convertible senior notes due 2025 (the "Notes") pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the "SEC") on Form S-3. The Company has also granted the underwriter a 30-day option to purchase up to an additional $75 million aggregate principal amount of Notes. The Company intends to use the net proceeds of this offering for general corporate and working capital purposes. The Notes will be convertible into cash, shares of the Company's common stock (plus, if applicable, cash in lieu of any fractional share), or a combination thereof, at the Company's election.
NEW YORK, NY / ACCESSWIRE / January 9, 2018 / It was a day of losses for ACADIA on Monday, closing the day down a little over 6% at $27.11. There was no major news from the company whose stock was trading ...
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding EXAS totaled $3.24 billion.
Small-caps and large-caps are wildly popular among investors, however, mid-cap stocks, such as Exact Sciences Corporation (NASDAQ:EXAS), with a market capitalization of $6.89B, rarely draw their attention from the investingRead More...
MADISON, Wis., Jan. 7, 2018 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company expects to report revenue between $86.9 million and $87.9 million for the fourth quarter ended Dec. 31, 2017, an increase of 148 percent from the same quarter of 2016. The company completed approximately 176,000 Cologuard tests during the fourth quarter of 2017, 115-percent growth from the same period of 2016. Nearly 11,000 health care providers ordered Cologuard for the first time during the fourth quarter ended Dec. 31, 2017. The number of providers who have ordered Cologuard since its launch increased to nearly 102,000 during 2017.
President and CEO of Exact Sciences Corp (NASDAQ:EXAS) Kevin T Conroy sold 123,512 shares of EXAS on 12/22/2017 at an average price of $52.58 a share.
MADISON, Wis., Dec. 20, 2017 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that its executives will be presenting at the following investor conference and invited investors to participate by webcast. The webcast can be accessed in the investor relations section of Exact Sciences' website at www.exactsciences.com. Exact Sciences Corp. is a molecular diagnostics company focused on the early detection and prevention of the deadliest forms of cancer.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to EXACT Sciences Corp. Here are 5 ETFs with the largest exposure to EXAS-US. Comparing the performance and risk of EXACT Sciences Corp. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives EXACT Sciences Corp. a score of 50. Our analysis is based on comparing EXACT Sciences Corp. with the following peers – Myriad Genetics, Inc., Genomic Health, Inc., Invacare Corporation, Antares Pharma, Inc., Veracyte Inc, Trovagene, Inc., GeneNews Limited, Vermillion, Inc., Foundation Medicine, Inc. and Biocept, Inc. (MYGN-US, ... Read more (Read more...)
Jim Cramer lifted the hood on Tesla’s move higher and why he thinks the stock rose despite fewer-than-expected Model 3 deliveries in Q4.
Jim Cramer caught up with Exact Sciences Chairman and CEO Kevin Conroy, who spoke to his biotechnology company's prospects relating to cancer.